Stan Wang has a knack for giving invisible work a memorable address. The thymus, he likes to explain, is the “schoolhouse for T cells.” It is a neat piece of translation: a walnut-sized organ becomes a campus, immature immune cells become pupils, and a dense corner of developmental biology becomes legible over coffee. Founders live or die by explanations. Scientists live or die by precision. Wang trained for both jobs.
By July 2026, the explanation had acquired an unusually concrete price tag. United Therapeutics bought Thymmune Therapeutics, the Cambridge company Wang founded in 2019, for $140 million in cash. The agreement added as much as $160 million in payments tied to clinical and regulatory milestones through 2031. Thymmune was still a preclinical company. The transaction therefore purchased a platform, a team and a thesis - with the hard evidence of human medicine still ahead.
That distinction matters. A biotech acquisition can look like the end of a founder story. In practice it is often a transfer of the laboratory keys, followed by more experiments, more manufacturing work and more meetings with regulators. The deal closed a chapter for Thymmune as an independent startup. It did not close the scientific question that had held Wang’s attention for years.
The long way to a small organ
Wang’s biography reads like a relay race run through the institutions that taught modern cell biology how to walk. He earned a bachelor’s degree at the University of Akron in 2009, where he was a Rhodes Scholar finalist and a student commencement speaker. He then moved to the University of Cambridge as a Gates Scholar and NIH-Cambridge Scholar. His doctoral supervisors included Roger Pedersen and Sir John Gurdon, whose work on cellular reprogramming earned Gurdon the 2012 Nobel Prize in Physiology or Medicine.
At the same time, Wang worked as a pre-doctoral fellow at the National Institutes of Health under Vittorio Sartorelli. The overlap is revealing. He was learning developmental biology in Cambridge and operating inside the American biomedical research system. In 2015 he completed his PhD in stem cell biology and regenerative medicine. In 2016, he received his medical degree from Columbia through its Medical Scientist Training Program.
There was an early public glimpse of the future Wang was imagining. In a 2013 TEDxOxbridge talk, he used Prometheus and his perpetually regenerating liver to introduce induced pluripotent stem cells. The talk is earnest, compact and very much of its scientific moment. Stem cells are presented not as magic but as a new set of tools for persuading mature cells to recover a wider range of possibilities. Years before he had a company focused on the thymus, Wang was already rehearsing how to explain regeneration without reaching for a wand.
“Its job is to basically be the schoolhouse for T cells.”Stan Wang, describing the thymus
Two startups, one manufacturing problem
After Columbia, Wang joined George Church’s lab at Harvard Medical School as a postdoctoral fellow affiliated with the Wyss Institute. Church’s orbit has produced a small constellation of companies, and Wang soon joined it. In 2017 he co-founded Cellino Biotech with Nabiha Saklayen and Marinna Madrid, serving as founding chief scientific officer. Cellino brought lasers, imaging and automation to the work of controlling and manufacturing cells. Wang is named on a patent for systems that use imaging and laser scanning to manage cells in culture.
Cellino and Thymmune look different from a distance. One develops manufacturing technology; the other develops a particular class of engineered thymic cells. Up close, the family resemblance is obvious. A scientific paper may show that a cell can be made. A therapy requires that cells be made reliably, repeatedly, at useful scale and under strict quality controls. Nature is an excellent inventor and a famously temperamental factory manager.
Wang left his operating role at Cellino in 2019 and founded Thymmune that July. The new company licensed foundational intellectual property from the University of California, San Francisco, where researchers had shown that stem-cell-derived thymic cells could support T-cell development in mice. Thymmune’s proposition was to turn that biological recipe into an off-the-shelf cell product, with machine learning and engineering methods helping optimize the process.
The first days were modest. Wang worked at a rented lab bench in Cambridge. The aim was not. Thymmune would begin with congenital athymia, a rare condition in which infants are born without a working thymus, then explore other applications if the initial approach proved safe and effective. This was the wedge: start where the need is severe and the organ’s function is unmistakable, then let evidence determine how far the platform might travel.
A public bet with milestones
The company’s most consequential validation before the acquisition arrived in September 2023. ARPA-H, the federal agency created to fund ambitious health research, awarded Thymmune up to $37 million for a two-phase Stem Cell-Derived Thymus Rejuvenation project. Wang and Thymmune co-founder Bing Lim were named principal investigators. The plan moved from improving the production of thymic epithelial cells toward transplantation, long-term engraftment and animal evidence that could support a path to human testing.
The award brought capital, scrutiny and a timetable. It also made the company part of an argument about what government research funding should do. Incremental science has many homes. ARPA-H was built for projects whose uncertainty is matched by their possible reach. Thymmune’s pitch fit: use engineered stem cells to produce tissue from an organ that conventional manufacturing cannot simply order by the pallet.
Wang’s language balanced the size of the vision with a sequence for approaching it. He spoke publicly about someday giving people a new thymus to “reboot” immune function as they age. In the same interview, he described the actual strategy as starting with the most clinically severe cases and working down, “while ensuring we have the safest product possible.” The dream was broad. The operating plan was a staircase.
“Our strategy will be to start from the most clinically severe and work our way down.”Stan Wang on sequencing the company’s work
The deal is a comma
United Therapeutics offered a particularly legible next home. Led by Martine Rothblatt, the public-benefit corporation has spent years working on organ alternatives, transplantation and cell-based technologies. Thymmune’s platform could sit beside those programs rather than explain itself from scratch. The buyer described the lead candidate, THY-100, as being in preclinical development and said animal studies had shown the formation of a neo-thymus capable of supporting T-cell development.
Cash paid upfront, subject to post-closing adjustments.
The economics preserve the uncertainty in plain numbers. The $140 million upfront payment recognizes what Thymmune had assembled. The potential $160 million recognizes what still must happen. Those contingent payments depend on clinical and regulatory milestones, not on how gracefully the founding story is told. Biology remains immune to narrative pressure.
For Wang, the sale links the newest chapter to the oldest. At Cambridge he studied how cells acquire and change identity. At the NIH and Harvard he worked inside large research systems. At Cellino he confronted the machinery required to control cells. At Thymmune he applied those lessons to one underappreciated organ. United Therapeutics now supplies a larger industrial setting in which the idea can be tested.
There is a tempting version of the story in which a founder notices what everyone else missed. The more interesting version is about accumulation. Wang did not discover the thymus. He collected enough perspectives to see it simultaneously as developmental biology, medicine, manufacturing and communication. His “schoolhouse” metaphor was not the insight itself. It was evidence that the insight had become portable.
That portability may be the quiet achievement. A neglected organ became a sentence a non-scientist could repeat, then a company a team could join, then a project a government agency could fund, then a platform a strategic buyer could acquire. Each translation carried the same idea into a room with different rules.
The deal gives the story a satisfying number. Science is less courteous. It will proceed at the pace of reproducible cells, convincing data and careful trials. Wang’s independent startup chapter has ended; his long experiment in making regenerative medicine manufacturable has not. Somewhere inside that distinction is the entire strange charm of biotechnology: the press release arrives on schedule, while the future keeps its own calendar.